Verona Pharma - VRNA Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings or view top-rated stocks.

6 equities research analysts have issued 12-month price objectives for Verona Pharma's stock. Their VRNA share price forecasts range from $27.00 to $32.00. On average, they anticipate the company's stock price to reach $29.33 in the next year. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for VRNA or view top-rated stocks among Wall Street analysts.

Verona Pharma's stock was trading at $26.13 on January 1st, 2023. Since then, VRNA shares have decreased by 22.1% and is now trading at $20.35.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our VRNA earnings forecast.

Verona Pharma plc (NASDAQ:VRNA) released its quarterly earnings data on Tuesday, March, 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06. The business earned $0.46 million during the quarter.

ETFs with the largest weight of Verona Pharma (NASDAQ:VRNA) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and iShares Biotechnology ETF (IBB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

(VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

Verona Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (8.35%), Fairmount Funds Management LLC (3.80%), Frazier Life Sciences Management L.P. (3.72%), Jennison Associates LLC (1.36%), Samsara BioCapital LLC (0.92%) and Two Sigma Investments LP (0.69%). Insiders that own company stock include Anders Ullman, Claire Poll, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Mark W Hahn, Orbimed Advisors Llc and Patrick John Finn.
View institutional ownership trends.

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRNA stock can currently be purchased for approximately $20.35.

Verona Pharma (NASDAQ:VRNA) has a market capitalization of $1.54 billion and generates $460,000.00 in revenue each year. The company earns $-68,700,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for the company is www.veronapharma.com. The company can be reached via phone at 011-44-0-2032834200 or via email at verona@argotpartners.com.